Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Jadi Cell
Elk City, Idaho, United Statestherapeuticsolutionsint.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
JadiCell mesenchymal stem cell therapy has demonstrated 100% survival in COVID-19 ARDS patients under age 85 in a double-blind Phase 1/2 trial, showing anti-inflammatory and regenerative effects superior to other stem cell sources; it is in Phase 3 for ARDS and has Right to Try and preclinical programs for various neuroinflammatory and neurodegenerative diseases
- Therapeutic areas
- Infectious DiseasesPulmonologyPsychiatryNeurology
- Modalities
- Cell therapyMesenchymal stem cellAdult stem cell therapy
- Industry
- Biotech
02
Partnerships
Therapeutic Solutions International (exclusive licensee for clinical use in brain and lung indications)Allogen Biologics (TSOI subsidiary; manufacturing partner for JadiCell products)
Beyond the preview
Go deeper on Jadi Cell.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Jadi Cell.